Medscape

Factor VIII May Predict Catheter-Related Thrombosis in Critically Ill Children

Setting: Two tertiary academic centers. Patients: We enrolled children younger than 18 years who were admitted to the PICU within 24 hours after insertion of a central venous catheter. We excluded ...
FierceBiotech

ThromboGenics and BioInvent Announce Positive Topline Results From Phase II VTE Prophylaxis Study With Anti-Factor VIII (TB-402)

ThromboGenics NV (Euronext Brussels: THR) and co-development partner BioInvent International (OMXS: BINV) announce today positive results from their Phase II trial of TB-402. TB-402 is a novel, long ...
Business Wire

Savaysa (Edoxaban; Daiichi Sankyo) Drug Overview 2017/18-2026 - A Direct Oral Factor Xa Inhibitor Indicated for the Treatment and Prevention of DVT and PE - ResearchAndMarkets.com

DUBLIN--(BUSINESS WIRE)--The "Drug Overview: Savaysa" report has been added to ResearchAndMarkets.com's offering. Savaysa (Edoxaban; Daiichi Sankyo) is a direct oral factor Xa inhibitor indicated for ...
FierceBiotech

BioInvent and ThromboGenics Announce Positive Topline Results from Phase II VTE Prophylaxis Study with Anti-Factor VIII (T

LUND, Sweden & LEUVEN, Belgium--(BUSINESS WIRE)-- BioInvent International AB (OMXS:BINV) and ThromboGenics NV (Euronext Brussels:THR) announce today positive results from their Phase II trial of ...